Wuhan Healthgen Biotechnology Corp

Wuhan Healthgen Biotechnology Corp. (Healthgen Biotech), specializing in molecular pharmaceutical research and development, is a private company founded in 2006. Healthgen Biotech is a national high and new biotech enterprise. Its commission is to use a state-of-art technology, rice endosperm cell specific expression platform (Oryz^HiExp), having high capacity to express proteins or small peptides in the rice grain, to develop the plant-made pharmaceuticals (PMP). The PMP provides a new approach for production of biopharmaceuticals. 

Healthgen Biotech’s state-of-the-art technology obtained a number of patents in China and international-wide. Utilizing Oryz^HiExp platform, Healthgen Biotech have achievements in developing and commercializing a series of products, including Recombinant Human Serum Albumin (OsrHSA), Recombinant Human basic Fibroblast Growth Factor (OsrhbFGF), Recombinant Human Fibronectin (OsrhFN), Recombinant Human α-1 Antitrypsin (OsrhAAT), Recombinant Human Epidermal Growth Factor (OsrhEGF), Recombinant Human Lactoferrin (OsrhLF), Recombinant Human Insulin-like Growth Factor-1 LR3 (rhIGF-1 LR3) , Recombinant Human  Epidermal Growth Factor (rhEGF) and Recombinant Human Fibronectin(OsrhFN). Meanwhile, Healthgen Biotech can provide customized protein or peptides expression services.